Last reviewed · How we verify

lithium plus valproate — Competitive Intelligence Brief

lithium plus valproate (lithium plus valproate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Mood stabilizer combination. Area: Psychiatry.

marketed Mood stabilizer combination GSK-3, inositol monophosphatase, histone deacetylase, GABA signaling Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

lithium plus valproate (lithium plus valproate) — University of Sao Paulo. Lithium and valproate together modulate neuronal signaling and gene expression through distinct pathways to stabilize mood and reduce manic or depressive episodes.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
lithium plus valproate TARGET lithium plus valproate University of Sao Paulo marketed Mood stabilizer combination GSK-3, inositol monophosphatase, histone deacetylase, GABA signaling
Risperidone, divalproex Risperidone, divalproex Nathan Kline Institute for Psychiatric Research marketed Atypical antipsychotic + anticonvulsant mood stabilizer combination Dopamine D2 receptor (risperidone); histone deacetylase / GABA pathway (divalproex)
Quetiapine and Topiramate Quetiapine and Topiramate University of Cincinnati marketed Atypical antipsychotic + anticonvulsant mood stabilizer combination D2 dopamine receptor, 5-HT2A serotonin receptor (quetiapine); voltage-gated sodium channels, carbonic anhydrase (topiramate)
sodium valproate with Clozapine sodium valproate with Clozapine Shanghai Mental Health Center marketed Antipsychotic + mood stabilizer combination Dopamine D2 receptor, serotonin 5-HT2A receptor, GABA pathways, histone deacetylase
lithium plus carbamazepine lithium plus carbamazepine University of Sao Paulo marketed Mood stabilizer combination Lithium: inositol monophosphatase and GSK-3β; Carbamazepine: voltage-gated sodium channels
Paroxetine+Lamotrigine Paroxetine+Lamotrigine Ministry of Health & Welfare, Korea marketed SSRI + anticonvulsant mood stabilizer combination Serotonin transporter (SERT); voltage-gated sodium channels; glutamate release modulation
Paroxetine+Lithium Paroxetine+Lithium Ministry of Health & Welfare, Korea marketed SSRI + mood stabilizer combination Serotonin transporter (SERT); inositol monophosphatase; protein kinase C

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Mood stabilizer combination class)

  1. University of Sao Paulo · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). lithium plus valproate — Competitive Intelligence Brief. https://druglandscape.com/ci/lithium-plus-valproate. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: